Continuous versus intermittent infusion of cefotaxime in critically ill patients: a randomized controlled trial comparing plasma concentrations

Heleen Aardema, Wouter Bult, Kai van Hateren, Willem Dieperink, Daan J Touw, Jan-Willem C Alffenaar, Jan G Zijlstra, Willem Dieperink

    Onderzoeksoutput: ArticleAcademicpeer review


    BACKGROUND: In critical care patients, reaching optimal β-lactam concentrations poses challenges, as infections are caused more often by microorganisms associated with higher MICs, and critically ill patients typically have an unpredictable pharmacokinetic/pharmacodynamic profile. Conventional intermittent dosing frequently yields inadequate drug concentrations, while continuous dosing might result in better target attainment. Few studies address cefotaxime concentrations in this population.

    OBJECTIVES: To assess total and unbound serum levels of cefotaxime and an active metabolite, desacetylcefotaxime, in critically ill patients treated with either continuously or intermittently dosed cefotaxime.

    METHODS: Adult critical care patients with indication for treatment with cefotaxime were randomized to treatment with either intermittent dosing (1 g every 6 h) or continuous dosing (4 g/24 h, after a loading dose of 1 g). We defined a preset target of reaching and maintaining a total cefotaxime concentration of 4 mg/L from 1 h after start of treatment. CCMO trial registration number NL50809.042.14, NCT02560207.

    RESULTS: Twenty-nine and 30 patients, respectively, were included in the continuous dosing group and the intermittent dosing group. A total of 642 samples were available for analysis. In the continuous dosing arm, 89.3% met our preset target, compared with 50% in the intermittent dosing arm. Patients not reaching this target had a significantly higher creatinine clearance on the day of admission.

    CONCLUSIONS: These results support the application of a continuous dosing strategy of β-lactams in critical care patients and the practice of therapeutic drug monitoring in a subset of patients with higher renal clearance and need for prolonged treatment for further optimization, where using total cefotaxime concentrations should suffice.

    Originele taal-2English
    Pagina's (van-tot)441-448
    Aantal pagina's8
    TijdschriftThe Journal of antimicrobial chemotherapy
    Nummer van het tijdschrift2
    StatusPublished - 1 feb. 2020


    • nierklaring functie
    • intensive care afdelingen
    • kritieke ziekte
    • plasmageneesmiddelconcentratie


    Duik in de onderzoeksthema's van 'Continuous versus intermittent infusion of cefotaxime in critically ill patients: a randomized controlled trial comparing plasma concentrations'. Samen vormen ze een unieke vingerafdruk.

    Citeer dit